dbo:abstract
|
- Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022. (en)
|
dbo:alternativeName
| |
dbo:casNumber
|
- 1187451-19-9
- 1187451-41-7
|
dbo:chEMBL
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 8388 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:atcSuffix
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chembl
|
- 3707245 (xsd:integer)
- 4297666 (xsd:integer)
|
dbp:chemspiderid
|
- 44210451 (xsd:integer)
- 57643658 (xsd:integer)
|
dbp:drugbank
| |
dbp:h
| |
dbp:iupacName
|
- Propan-2-yl 2-6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate (en)
|
dbp:jan
|
- Omidenepag isopropyl (en)
|
dbp:kegg
| |
dbp:legalStatus
| |
dbp:legalUs
| |
dbp:n
| |
dbp:o
| |
dbp:pubchem
|
- 44230575 (xsd:integer)
- 44230999 (xsd:integer)
|
dbp:routesOfAdministration
| |
dbp:s
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- VIQCWEGEHRBLAC-UHFFFAOYSA-N (en)
- YHGSTSNEOJUIRN-UHFFFAOYSA-N (en)
|
dbp:synonyms
| |
dbp:tradename
| |
dbp:unii
|
- G0G0H52U6K (en)
- Z95F9F9LU4 (en)
|
dbp:wikiPageUsesTemplate
| |
dct:subject
| |
rdf:type
| |
rdfs:comment
|
- Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |